+39 02 610346.1 - info@newron.com

J. Donald (Don) deBethizy

J. Donald (Don) deBethizy

Don deBethizy, a director since 2014, has more than 20 years of experience in managing and financing life science-related technologies and has played a key role in building and advising several life science companies. In his role as President, Chief Executive Officer and Director on the Board of Santaris Pharma A/S, he led the sale of the company to Roche. He cofounded Targacept, Inc. and served as its President and Chief Executive Officer fro 15  years. Donald led Targacept’s private and public financings totaling approximately $330 million, including the Company’s Initial Public Offering (IPO) in April 2006. He played a key role in developing business relationships with GlaxoSmithKline, AstraZeneca, Aventis, and Dr. Falk Pharma, which generated non-dilutive revenues totaling over $300 million. He holds a B.S. in Biology from University of Maryland and an M.S. and PhD from Utah State University. He is currently President of Innovent LLC (USA) and White City Consulting ApS (Denmark), Managing Director of Albumin Holding ApS, a Director at argenx NV (Netherlands), Noxxon Pharma NV (Netherlands) and Proterris Inc (USA), as well as Chairman of the boards of Albumedix Ltd (UK), Saniona AB (Denmark). Don is the Chairman of Newron’s R&D committee and, since May 2019, member of the audit and risk committee. He is a U.S. citizen and resident of Denmark.